A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.

Trial Details

NCT ID
NCT07428616
Phase
PHASE2
Sponsor
Exelixis
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Zanzalintinib
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366
  • Houston, Texas, United States|29.76328,-95.36327
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Histologically confirmed World Health Organization (WHO) grade 1, 2, or 3 meningioma.
  • Developed recurrent disease or progressive disease (PD) after receiving standard therapy (for example, surgery and/or radiation) or have been deeme…
  • Radiologically documented progression of any existing tumor (growth \> 15% of the bidimensional enhancing tumor within the prior 6 months or appear…
  • For participants treated with external beam radiation, interstitial brachytherapy, or radiosurgery, an interval ≥ 24 weeks must have elapsed from c…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →